This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Albensi, B. C. Articles by Ilkanich, E. Search for Related Content PubMed PubMed Citation Articles by Albensi, B. C. Articles by Ilkanich, E. Social Bookmarking                         What's this?

Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?

Center for Cerebrovascular Research, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Department of Biology, Case Western Reserve University, Cleveland, Ohio

Chiazor Igoechi, BS

Department of Biology, Case Western Reserve University, Cleveland, Ohio

Damir Janigro, PhD

Center for Cerebrovascular Research, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University

Erin Ilkanich, BS

Department of Biology, Case Western Reserve University, Cleveland, Ohio

Similar to drug development programs for stroke and traumatic brain injury, programs developed for Alzheimer's disease (AD) have not been very effective in treating dementia. Recently, researchers have explored modulating excitatory synaptic neurotransmission via the N-methyl-D-aspartate receptor (NMDAR) to treat AD. However, many investigators doubt that NMDA antagonists are safe and effective for treating persons with AD because they have failed in stroke and trauma programs. This article explores the role of NMDA-mediated excitotoxicity in AD, reviews how the NMDAR functions, highlights the side effects and alternate signaling pathways that are initiated from NMDAR activation, provides examples of NMDA antagonists that do not exhibit the typical side effects, and discusses why some NMDA antagonist compounds are effective and safe in limiting cascades of excitotoxicity in dementia or acute brain injury.

Key Words: dementia • brain injury • NMDA antagonist • NMDAR • Alzheimer's disease • excitotoxicity

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 19, No. 5, 269-274 (2004)
DOI: 10.1177/153331750401900502


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Liu, T. P. Wong, M. Aarts, A. Rooyakkers, L. Liu, T. W. Lai, D. C. Wu, J. Lu, M. Tymianski, A. M. Craig, et al. NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death Both In Vitro and In Vivo J. Neurosci., March 14, 2007; 27(11): 2846 - 2857. [Abstract] [Full Text] [PDF]

				C. F. Lippa An Individualized Approach to Treatment for Alzheimer's Disease, Pick's Disease, and Other Dementias. American Journal of Alzheimer's Disease and Other Dementias, October 1, 2006; 21(5): 354 - 359. [Abstract] [PDF]